• Competent to comprehend, sign, and date an independent ethics committee/institutional review board/research ethics board (IEC/IRB/REB) approved informed consent form.

• Male or female subjects aged 18 to 75 years (including 18 and 75 years).

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Histopathological diagnosed of locally advanced or metastatic triple negative breast cancer. Not suitable for radical therapy.

• Subjects who have failed standard treatment or naive to systemic antitumor therapy in advanced setting.

• Subjects must submit tumor tissues for test.

• Life expectancy of ≥ 12 weeks.

• Subjects must have measurable disease according to RECIST (version 1.1).

• Adequate organ functions.

⁃ Sexually active fertile subjects, and their partners, must agree to use methods of contraception during the study and at least 6 months after termination of study therapy.

⁃ Subjects are willing to follow study procedures